Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

• Status: Terminated
• Trial end date: 2019-01-17
• Target enrollment: 0
• Participant gender: All

Summary

This study seeks to evaluate the long-term safety and effectiveness of nelotanserin for the treatment of visual hallucinations (VHs) and Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with Lewy body dementia (LBD).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Axovant Sciences Ltd.

Criteria

Inclusion Criteria:

• Subjects with LBD who completed a previous nelotanserin VH or RBD study

Exclusion Criteria:

• Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder